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Abstract
Background: Even though two prophylactic vaccines against HPV are currently licensed, infections by the
virus continue to be a major health problem mainly in developing countries. The cost of the vaccines limits
wide-scale application in poor countries. A promising strategy for producing affordable and efficient
vaccines involves the expression of recombinant immunogens in plants. Several HPV genes have been
expressed in plants, including L1, which can self-assemble into virus-like particles. A plant-based, dual
prophylactic/therapeutic vaccine remains an attractive possibility.
Results: We sought to express in tomato plants chimeric HPV 16 VLPs containing L1 fused to a string of
epitopes from HPV 16 E6 and E7 proteins. The L1 employed had been modified to eliminate a strong
inhibitory region at the 5' end of the molecule to increase expression levels. Several tomato lines were
obtained expressing either L1 alone or L1-E6/E7 from 0.05% to 0.1% of total soluble protein. Stable
integration of the transgenes was verified by Southern blot. Northern and western blot revealed successful
expression of the transgenes at the mRNA and protein level. The chimeric VLPs were able to assemble
adequately in tomato cells. Intraperitoneal administration in mice was able to elicit both neutralizing
antibodies against the viral particle and cytotoxic T-lymphocytes activity against the epitopes.
Conclusion: In this work, we report for the first time the expression in plants of a chimeric particle
containing the HPV 16 L1 sequence and a string of T-cell epitopes from HPV 16 E6 and E7 fused to the C-
terminus. The particles were able to induce a significant antibody and cytotoxic T-lymphocytes response.
Experiments in vivo are in progress to determine whether the chimeric particles are able to induce
regression of disease and resolution of viral infection in mice. Chimeric particles of the type described in
this work may potentially be the basis for developing prophylactic/therapeutic vaccines. The fact that they
are produced in plants, may lower production costs considerably.
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Background
The human papillomaviruses (HPV) comprise a heteroge-
neous group of more than 130 epitheliotropic genotypes,
16 of which are considered "high-risk" types and linked
with the development of malignant disease [1]. High-risk
types, HPV 16 and HPV 18, are the main etiological agents
of cervical cancer, with HPV 16 being involved in about
half of all cases of cancer [2]. HPV are responsible for
approximately half a million new cervical cancer cases
every year and almost 250,000 deaths per year, most of
them occurring in developing countries [2]. Among the
various HPV components, the major structural protein of
the capsid, L1, has been the antigen of choice for the
development of prophylactic vaccines. L1 can self-assem-
ble into virus-like particles (VLPs), which are very efficient
in inducing an immune response. VLP-induced antibod-
ies provide protective immunity against challenge with
infectious viruses in animal models [3,4]. Two L1-based,
HPV vaccines have been licensed in several countries after
demonstration of an acceptable benefit/risk profile [5],
one (Gardasil®) contains two high-risk (16 and 18) and
two low-risk (6 and 11) types and the other (Cervarix®) is
composed of two high-risk types, 16 and 18.
Parenteral vaccines, such as that for HPV, are expensive to
produce and costly to administer. Thus, many diseases
that are controlled effectively in industrialized countries
are controlled poorly at best in poor countries. A promis-
ing strategy for producing affordable and efficient vac-
cines involves the expression of recombinant
immunogens in plants. Plants provide a number of
advantages for production of recombinant proteins over
conventional systems including low cost, increased safety
and scalable production [6]. They are a potential source of
a wide range of biopharmaceuticals that is not dependent
upon downstream processing technology to ensure pro-
tein folding, particle assembly and stability. In conse-
quence, a plant-based biopharmaceutical expression
system makes possible either testing of an oral therapy
strategy by simply feeding with edible plant tissues or
purification of the compound from the plant, which
would reduce processing costs. A number of antigens
from different origins have been expressed in various
plants and HPV antigens have been no exception. Plants
such as tobacco, potato, tomato and Arabidopsis have
been employed for the production of human and animal
papilloma L1 VLPs, which appeared similar in size and
structure to authentic papilloma virus VLPs as shown by
electron microscopy studies [7-14]. In addition, plant-
produced VLPs were immunogenic when administered in
mice either orally or intraperitonally [7,8,14].
On the other hand, since capsid proteins are not expressed
at detectable levels by HPV-transformed cells, therapeutic
vaccines generally target the nonstructural early viral anti-
gens. The E6 and E7 oncogenic proteins, which are critical
to the induction and maintenance of cellular transforma-
tion and co-express in the majority of HPV-containing car-
cinomas, are potential targets in the development of an
immunotherapy against HPV infection [15,16]. Although
other early viral antigens show promise for vaccination
against papillomas, therapeutic vaccines targeting E6 and
E7 may provide the best opportunity to control HPV-asso-
ciated malignancies. These proteins have been demon-
strated to contain several reactive T-cell epitopes which
may play a role as tumor rejection antigens in humans
[17]. Cell-mediated immunity responses to these epitopes
correlates significantly with regression of disease and res-
olution of viral infection within 12 months [18,19]. Since
HPV VLPs can be employed as vehicles to deliver epitopes
or genes [20], we hypothesized that chimeric VLPs
(cVLPs) containing L1 fused to T-cell epitopes from E6
and E7 might be able to elicit both neutralizing antibodies
against the viral particle and cytotoxic T-lymphocytes
(CTL) activity against the epitopes and induce regression
of disease and loss of HPV infection. In this work, we
report for the first time the expression of a chimeric parti-
cle containing the HPV 16 L1 sequence and a string of T-
cell epitopes from HPV 16 E6 and E7 fused to the C-termi-
nus. The particle was expressed in tomato cells and was
able to stimulate significant antibody and cell-mediated
immune responses in mice.
Results
Tomato plant transformation with LI-E6/E7 fusion gene 
constructs
We transformed tomato cotyledons with the construct LI-
E6/E7-2300 or with L1 alone via A. tumefaciens infection.
We employed the modified L1 cDNA reported by Collier
et al [21], in which the strong inhibitory elements located
in the first 514 nucleotides of the L1 gene were modified.
A synthetic peptide containing three E7 and one E6
epitopes mediating cytotoxic activity [18,19,17] was fused
to the C terminus of the optimized L1, which removed the
last 34 amino acids at the 3' end. We recovered 9 plants for
L1 and 5 for LI-E6/E7 on selective medium which were
grown in the greenhouse to maturity and selfed. These
plants were tested for NPTII expression. Their progeny was
analyzed by Southern blot and employed for subsequent
experiments. Of nine lines found to express L1 mRNA,
only two presented a normal phenotype. The rest of the
lines were not transferred to the greenhouse due to poor
growth of tissue culture plantlets or because they showed
stunted growth in the greenhouse and did not flower in
time (data not shown). Of five lines expressing LI-E6/E7,
we were able to recover only three.
L1 expression at the transcriptional and translational level
Integration of L1 or LI-E6/E7 fusion in the tomato lines
was confirmed by Southern blot hybridization. We foundVirology Journal 2009, 6:2 http://www.virologyj.com/content/6/1/2
Page 3 of 11
(page number not for citation purposes)
that the two lines expressing L1 contained one copy
whereas all three lines transformed with L1-E6/E7 con-
tained also a single copy of the transgene (Fig. 1). DNA
from wild type plants did not hybridize with the probe.
Total RNA isolated from wild type and transfected lines
was used to determine L1 and L1-E6/E7 mRNA expression
by northern blotting. As Fig. 2 shows, mRNA is accumu-
lated to comparable levels in the two lines of L1 and in the
two lines of L1-E6/E7. The latter displayed slightly higher
accumulation that in L1 lines. One of the L1-E6/E7 lines,
showed a band of lower intensity than the rest (Fig. 2).
Western blot analysis showed a ≈55 kDa band present in
fruit extracts from all lines and reacting with specific anti-
bodies against L1 (Fig. 3). The band was not detectable in
protein extracts from non-transformed fruit. Additional
bands were also detectable by the antibodies in the case of
lines transformed with L1-E6/E7. This could be due to
processing of the recombinants proteins by an unknown
protease or alternatives origins of translation at the L1 and
L1E6/E7 sequences. One of the lines displayed a very faint
band and it corresponds to the line yielding a band of low
intensity in western blot. No signal was detected in
untransformed plant sample.
The amount of L1 and L1-E6/E7 protein in tomato plant
extracts was determined by ELISA at 405 nm using the
commercial vaccine as standard. Yields of L1 protein har-
vested from tomato fruits were calculated to be between
0.05% to 0.1% of total soluble protein. When we deter-
mined by ELISA the expression of L1-E6/E7 in T2 plants
from one of our lines, we found that the levels in the fruit
were similar to the parent plant (data not shown), indicat-
ing that expression of the transgene is stable through gen-
erations. The lines presenting the highest expression levels
were selected for further work.
Electron microscopy
L1 can self-assemble into VLPs in plant cells as noted
before. We were interested to determine whether the
plant-based, optimized L1 fused to the string of epitopes
was able to assemble into chimeric VLPs. To this end we
employed electron microscopy. As Figure 4 shows, VLPs
of about 50–60 nm in diameter were observed in protein
extracts obtained from tomato lines containing L1-E6/E7
which looked similar identical to LI particles. Protein
extracts derived from non-transfected tomato fruits did
not show any particles. Addition of the 50 amino acids
containing the epitopes did not seem to affect assembly of
the particles.
Immunogenicity of plant-derived HPV-16 L1
It was important to determine if the plant-based particles
could induce an HPV-16 L1 immune response and, sec-
L1 HPV-16 transgenes integration Figure 1
L1 HPV-16 transgenes integration. Twenty micrograms 
of genomic DNA were extracted from tomato leaves as 
described in the text and restricted with EcoRI, separated by 
agarose electrophoresis and blotted on to Hybond-N+ nylon 
membrane. The membrane was hybridized with the 670 bp 
EcoRI/BamH1 fragment of the HPV-16 L1 gene. (A) Trans-
genic lines L1. (B) Transgenic lines L1-E6/E7. wt: non-trans-
formed plant. Molecular weight markers are indicated on the 
right.
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ondly, if the E6/E7 epitopes displayed by the chimeras
were immunogenic. Mice sera were collected 15 days after
the last immunization and evaluated by ELISA. The results
indicated that immunization with plant-based recom-
binant VLPs was associated with a significant serum anti-
body responses (Fig. 5A). The response was comparable to
that obtained with an equivalent amount of commercial
vaccine. Mice receiving only the adjuvant demonstrated
no response at any time by ELISA.
To investigate whether the antibodies induced by the par-
ticles were neutralizing, we employed an indirect assay.
The assay was based on the fact that VLPs interact with cell
receptors present in the membranes of erythrocytes,
resulting in agglutination [22]. Therefore we performed
serial dilutions of mice sera and each dilution was incu-
bated primarily with purified VLPs and subsequently with
erythrocytes from mouse. As shown in figure (5B), anti-
bodies from mice immunized with VLP, cVLP and com-
mercial vaccine were able to inhibit hemagglutination
completely from dilution 1:400. Once again, inhibition of
hemagglutination of the plant-based VLPs was compara-
ble to that of the commercial vaccine. In contrast, sera
from mice immunized with adjuvant alone did not
inhibit agglutination at any dilution (Fig. 5B).
Cytotoxic activity of T cells obtained from mice immunized 
with VLPs
In order to investigate the cellular immune response of
mice immunized with plant-based VLPs, T-CD8+ cells
were isolated from spleens and incubated in vitro with
purified VLPs in the presence of IL-2. Subsequently, CTL
activity was determined on a tumor epithelial cell line
Northern blot analysis of the recovered tomato lines  expressing HVP16 L1 mRNA Figure 2
Northern blot analysis of the recovered tomato lines 
expressing HVP16 L1 mRNA. Total RNA was extracted 
from tomato fruits and 20 μg were fractionated by gel elec-
trophoresis and processed as described in the legend to Fig. 
1. The autoradiography (top panel) and the ethidium bro-
mide stained gel (bottom panel) are shown. a and b, Trans-
genic lines L1. c, d and e, Transgenic lines L1-E6/E7. wt, non-
transformed plant.
a b  c  d e wt
Analysis of soluble protein extracts by immunodetection Figure 3
Analysis of soluble protein extracts by immunodetec-
tion. Total proteins were extracted from tomato fruit from 
the T1 generation and 40 μg were loaded per lane, separated 
by 12% SDS PAGE, transferred onto a PDVF membrane, 
incubated with a mouse monoclonal anti-L1 antibody and the 
bands detected by chemiluminescence as described in the 
text. Top panel, transgenic lines L1. Bottom panel, transgenic 
lines L1-E6/E7. mwm molecular weight markers, wt non-
transformed tomato plant. The arrows indicate the bands 
present in transformed plants but not in non-transformed 
plants. Additional bands detected by the antibody can be 
seen in the bottom panel.
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from mouse lung co-transfected with E6 and E7 (from
HPV 16) and c-Ha-ras, denominated TC-1 [23] as well as
on TC-1 cells expressing the L1 HPV 16 gene (TC-1/L1). As
Fig. 6A shows, only T-CD8+ cells derived from mice
immunized with cVLPs were able to lyse TC-1 cells,
whereas T-CD8+ cells from mice immunized with VLP did
not present this activity. However, when TC-1/L1 cells
were employed, both cVLPs and VLPs were able to lise TC-
1 cells (Fig. 6B). Similar results were obtained when T-
CD8+ cells from mice immunized with commercial vac-
cine were incubated with TC-1/L1 cells (Fig. 6D). These
results suggested that immunization with both types of
plant-based VLPs elicit the generation of T cells specific to
epitopes from L1 or from E6/E7 insert. To investigate fur-
ther this possibility, C57BL/6 mice were immunized with
the epitope RAHYNIVTF derived from E7, which is
included in the cVLPs. As can be observed in Fig. 6C, T-
CD8+ cells obtained from the spleen of these mice were
also able to lyse TC-1 cells, which confirms that CTL activ-
ity of cVLPs is conferred by the string of epitopes.
Discussion
In this work we report for the first time the expression of
L1-based chimeric VLPs from HPV-16 containing a string
of epitopes from E6 and E7 HPV-16 proteins. There have
been a few instances of chimeric VLPs produced in other
systems (baculovirus, yeasts, E. coli) but not in plants.
Only a low number of transgenic plants containing the L1
constructs could be recovered, suggesting that L1 expres-
sion may interfere with plant growth and viability. Similar
results had been obtained previously in potato expressing
L1 [14]. Since expression of native or plant codon opti-
mized L1 was problematic in plants, resulting in low
expression levels, we had decided to employ the opti-
mized L1 cDNA reported by Collier et al. [21], since the
highest expression in plants had involved a codon-opti-
mized gene [11]. The levels of expression obtained in this
work (0.05% – 0.1% TSP) were higher or comparable to
what had been reported in previous works, 23 ng/g, 0.2%
TSP and .034–.076% TSP in potato and tobacco [7,10,14],
but they are not comparable to what Maclean et al. [11]
obtained using chloroplast transformation (11% TSP).
Nevertheless, we were still able to purify VLPs in sufficient
amounts to perform the immunization experiments.
HPV L1 VLPs can tolerate foreign peptides within the sur-
face-exposed areas. Regions of the C terminus can be
deleted and replaced with heterologous amino acids with-
out loss of VLP structure. Muller et al. [24] removed the
last 34 amino acids from the C terminus of HPV 16 L1 and
replaced them with an E7 fragment of 50 amino acids and
the VLPs could still assemble. Furthermore, it had been
reported that up to 60 amino acids could be cloned fused
to the C-terminus of L1, and VLPs would still be formed
[25]. We removed the last 34 amino acids from the C ter-
minus, inserting 50 amino acids and the particles assem-
bled adequately. Analysis of the tomato lines obtained
showed that they contained only one copy of the trans-
gene, whereas the mRNA of VLPs and cVLPs accumulated
to high levels in fruits of all lines. A band displaying the
same size as that obtained from the commercial vaccine
was detectable by specific antibodies in fruit from all lines
indicating successful expression in tomato. The plant-pro-
duced VLPs were able to induce neutralizing antibodies in
mice immunized intraperitonally as demonstrated by a
hemagglutinin inhibition assay. Previously L1-based VLPs
alone had been produced in plants and demonstrated to
be immunogenic in mice when administered either orally
or intraperitonally [7,8,14]. Our results are confirmatory
of those findings but it was important to demonstrate that
our chimeric particles also possess prophylactic as well as
therapeutic properties (see below). Interestingly, the E6 T-
cell epitope employed in this work, had not been included
in cVLPs before.
VLP and cVLP structures formation Figure 4
VLP and cVLP structures formation. Crude extracts of tomato fruit were processed as described in the text and nega-
tively-stained with 2% phosphotungstic acid for 5 min. The samples were imaged on a Philips Morgagni 268 transmission elec-
tron microscope. The arrows indicate the putative VLPs observed. (A) Commercial vaccine Gardasil® as control. (B) 
Transgenic lines with L1. (C) Transgenic lines with L1-E6/E7. (D) non-transformed plant. Bars indicate 0.1 μm.
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Since we are interested in producing a prophylactic/thera-
peutic preparation it was important to investigate whether
the presence of the string of epitopes could elicit any T cell
cytotoxic activity. Previously, Castellanos et al [26] had
tested a series of different epitopes from E6 and E7 HPV-
18 and found that only two of them (from E7) were able
to induce cell lysis in vitro. Our approach is different in
that we combined a prophylactic/therapeutic preparation.
The epitopes employed in this work had been reported as
tumor rejection antigens, causing regression of disease
and resolution of viral infection [17-19]. Our results indi-
cate that immunization with plant-based cVLPs elicits the
generation of CTL activity against the epitopes present in
the particle. This conclusion is supported by the results of
immunization with the E7 epitope RAHYNIVTF alone
which yielded similar results to those obtained with
immunization with cVLPS. VLPs alone or the commercial
vaccine did not present this activity. These results are in
agreement with previous experiments using cVLPs pre-
pared in baculovirus or E. coli. For example, Schafer et al.
[25] inserted 60 N-terminal amino acids of the HPV-16 E7
protein into the C-terminus of L1. These chimeric particles
induced conformational antibodies against L1 and a
robust CTL response against E7 in mice. Kuck et al. [27]
produced in baculovirus HPV 16 cVLPs containing L1
fused to the first 60 amino acids from E7 and were able to
not only induce L1-specific antibodies but also L1- and
E7-specific CTL responses after DNA vaccination. Bian et
al. [23] using a similar approach, produced in E. coli HPV-
16 capsomers containing the first 60 amino acids from E7.
These capsomeres were able to induce conformational
and neutralizing antibodies against HPV virus-like parti-
cles and trigger cell-mediated specific immune responses
against the L1 and E7 peptides. Freyschmidt et al. [28] pre-
pared HPV 16 cVLPs L1-E7 fusion proteins and in preclin-
ical studies the cVLPs were shown to induce neutralizing
antibodies and L1- and E7-specific T cell responses. Chi-
meric VLPs with L1 and E7 have been employed in clinical
trials but there was a poor match between the clinical
response and the immune response induced within the
individual patients [for a review see [29]]. For that reason,
Freyschmidt et al. [28] emphasized the need of improved
immunogenicity in future clinical trials and to that end
they employed lipopolysaccharides, unmethylated CpG
motifs and sorbitol, which substantially increased the
immunogenicity of cVLPs.
Chimeric VLPs have also been prepared by fusing L1 to
HPV genes such as L2, E1 and E2. However, the use of
these genes for therapeutic purposes is still somewhat
controversial because the T cell response to them is not
too well defined [30,31]. In this work, we decided to
employ well defined T-cell epitopes from E6 and E7
mainly because of their proven effects and because the
immune response to some of these epitopes had been
reported not to be HPV type-specific [17-19]. This
approach presents the additional advantage that the
length of the fused insert to L1 can be kept within the min-
imum necessary to allow formation of VLPs by a judicious
choice of epitopes. The order of the epitopes seems to be
important. A specific order of epitopes may have dramatic
may effects and altering that order may boost or diminish
the response [32,33]. It remains to be determined whether
the CTL response can be boosted by altering the order of
our epitopes. HPV VLPs have been postulated as ideal
vehicles to deliver epitopes or genes and for that reason a
wide range of foreign peptides have been fused and
expressed as chimeric VLPs in different systems or admin-
istered as DNA [20]. Many of this cVLPS have shown anti-
tumoral activity [29]. Cellular immune responses are
Determination of the antibodies response of mice to VLPs by  ELISA and hemmaglutination inhibition assay Figure 5
Determination of the antibodies response of mice to 
VLPs by ELISA and hemmaglutination inhibition 
assay. Groups of C57BL/6 mice were immunized with 
Gardasil® and with purified VLPs and cVLPs derived from 
tomato fruits. Serum was collected from each mice and used 
for: A, determination of antibodies against different types of 
VLPs by ELISA. Bars, mean and SE (n = 6). Sera dilution 
1:100. B, hemagglutination inhibition assay: sera from C57BL/
6 mice (n = 6 in all cases) immunized with Gardasil®, VLPs 
and cVLPs and the pre-immune group were assayed at 
1:1600, 1:800, 1:400, 1:200 and 1:100 dilutions as described 
in the text. (-), negative control (erythrocytes in the absence 
of VLPs), 100 ng of VLPs (a), cVLPs (b), and Gardasil® (c). 
VLPs incubated with erythrocytes were used as positive con-
trols for the hemagglutination assay.
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essential in controlling cervical cancer and in most cases
cVLPs are able to fully activate dendritic cells, and are sub-
sequently capable of inducing endogenously processed,
epitope-specific human T-cell responses in vitro [34,35].
Dendritic cells are the most potent inducers of immune
responses and play a central role in VLP-induced immu-
nity. Hence, cVLPs may prove fundamental for the devel-
opment of therapeutic vaccination.
An ideal HPV vaccine should be prophylactic as well as
therapeutic. Our results demonstrate for the first time the
production in plants of chimeric VLPs containing a L1-
based VLPs fused to a string of epitopes from E6 and E7
proteins, which were able to elicit humoral and CTL activ-
ity. The use of plants for production of a cost-effective,
efficient HPV vaccine remains a very attractive possibility,
currently investigated by several groups, including ours.
As Freyschmidt et al. [28] indicate, inclusion of an appro-
priate adjuvant may alleviate the problem of low immu-
nogenicity.
Conclusion
We report for the first time the expression in plants of a
HPV 16 L1-based cVLPs containing a string of T-cell
epitopes from HPV 16 E6 and E7 fused to the C-terminus.
The chimeric particles were able to induce neutralizing
antibody and a significant cytotoxic T-lymphocytes activ-
ity. Experiments in vivo are in progress to determine
whether the chimeric particles are able to induce regres-
sion of disease and resolution of viral infection in mice.
Immunization with VLPs and cVLPs induce cytotoxic specific T-lymphocytes in C57BL/6 mice Figure 6
Immunization with VLPs and cVLPs induce cytotoxic specific T-lymphocytes in C57BL/6 mice. T lymphocytes 
derived from C57BL/6-immunized mice with Gardasil® (n = 6), VLPs (n = 3) or cVLPs (n = 6), as well as with the HPV 16 E749-
57 (RAHYNIVTF, H-2Db-restricted) epitope (n = 6), were restimulated in vitro with the epitopes HPV 16 E749-57 
(RAHYNIVTF, H-2Db-restricted) and HPV 16 L1 165–173 (AGVDNRECI, H-2Db-restricted) and their cytolytic activity was 
tested by a standard 4-h 51Cr release assay against TC-1 cells A and C; and on HPV 16 L1-transfected TC-1 cells (TC-1/L1) B 
and D. T:E, target effector cells ratio.
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Chimeric particles of the type described in this work may
potentially be the basis for developing prophylactic/ther-
apeutic vaccines. The fact that they are produced in plants,
may lower production costs considerably.
Materials and methods
Construction of the chimeric VLP and tomato transfection
An HPV-16 L1 sequence in which inhibitory sequences
had been modified at the 5' end [21] was amplified by
PCR using specific primers and cloned into pCAMBIA
2301 between the promoter and terminator of 35S CaMV.
The forward primer was: 5'-CCGGAATTCATGAGCCTGT-
GGC-3' and the reverse primer was: 5'-ATTGGGTACCTT-
ACAGCTTACG-3'. We synthesized a sequence containing
a string of epitopes mediating T-cell cytotoxic activity
from the E6 and E7 HPV-16 genes [17-19]. The synthesis
was performed by GenScript http://www.genscript.com.
The string of epitopes (EIDGPAGQAEPDRAHYNIVTF-
PARKLPQLCTELQTTITLGIVCPISEKDEL) included amino
acids 16–30 from E6 and 37–54, 49–57 and 86–93 from
E7, ending with the signal for retention in the endoplas-
mic reticulum, SEKDEL. This sequence was fused in-frame
at the 3' end of the L1 HPV-16 gene by replacing the 34-
carboxy-terminal amino acids of the structural protein by
PCR as described by Muller et al. [24], to generate the chi-
merical construct LI-E6/E7 (Fig. 7). The construct was ver-
ified by sequencing and inserted between the promoter
and polyadenylation signal of CaMV 35S, between the
XhoI/KpnI restriction sites. The whole plant expression
cassette was inserted into the binary Ti plasmid pCAMBIA
2300 to obtain the LI-E6/E7-2300 construct, which was
transferred by electroporation into Agrobacterium tumefa-
ciens  strain LBA4404, and used for transformation of
tomato cotyledons (Lycopersicon esculentum Mill).
Tomato plants transfection has been described in detail
previously [36]. We employed the TA234 genotype kindly
donated by Prof. Steve Tanksley from Cornell University.
Putative transfected plants selected by kanamycin resist-
ance were transferred to soil and grown in the greenhouse.
Seeds from selected plants were collected, surface steri-
lized with 20% commercial blanch and 0.1% Tween 20
for 15 min and germinated on MS medium supplemented
with 100 mg/1 kanamycin. Seeds from T0 transgenic
plants were surface sterilized and germinated on rooting
medium with 100 mg/l kanamycin. Transfected plantlets
were grown in the greenhouse and utilized for further
experiments. Integration of LI-E6/E7 HPV-16 fusion gene
and chimeric protein in tomato plants was confirmed by
Southern blot hybridization and expression was con-
firmed by northern and western blot analysis.
Southern and northern blot analysis
For Southern analysis, genomic DNA was isolated from
young leaves as described by Gutiérrez Ortega et al. [36].
Twenty micrograms of DNA were digested with EcoRI,
which cuts only one in the gene, resolved by agarose elec-
trophoresis and blotted on to Hybond-N+ nylon mem-
brane (Amersham Pharmacia Biotech) as described by
Sambrook et al. [37]. The membrane was hybridized to a
radioactively labeled probe synthesized with the
Rediprime II kit (Amersham Pharmacia Biotech) using as
template a 670 bp EcoRI/BamH1 fragment of LI-E6/E7
HPV-16 gene (Fig. 7). Hybridization was performed in the
Rapid-Hyb buffer (Amersham Pharmacia Biotech) and
the membrane was exposed to Kodak Biomax Film
(Kodak) at -70°C. For northern analysis, total RNA was
extracted from fruit with the Concert Plant RNA Reagent
(Invitrogen) and 20 μg fractionated by denaturing formal-
dehyde gel electrophoresis [37]. Blotting, hybridization
and exposure were done as described above. The probe
was the same as that used for Southern analysis.
Sample preparation and western blot analysis
Tomato fruits were ground in liquid nitrogen and homog-
enized in 4 volumes of ice-cold extraction buffer (0.01 M
Na2HPO4, 0.002M KH2PO4, 0.137 M NaCl, 0.027 M KCL
and 0.025 M sodium ascorbate) in the presence of 1 mM
phenylmethylsulphonyl fluoride (PMSF) or protease
inhibitors cocktail (Sigma-Aldrich). Cleared supernatants
were collected after centrifugation at 13,000 rpm for 10
min at 4°C and employed for western blot analysis and
LI-E6/E7 HPV-16 determination by ELISA. Forty micro-
grams of total soluble protein aliquots, as determined by
Bradford [38], were resuspended in loading buffer (0.1 M
Tris pH 8.0, 2% SDS and 0.75 M β-mercaptoethanol),
boiled for 5 min, resolved by 12% SDS-PAGE and electro-
transferred on to polyvinylidene difluoride (PVDF) mem-
brane. The membrane was subsequently blocked with 8%
non-fat milk, 0.1% Tween-20 in TBS for 1 h at room tem-
perature. Mouse monoclonal anti-L1HPV 16 (Chemicon)
at 1:500 and HRP conjugated goat anti mouse IgG (Amer-
sham Pharmacia Biotech) at 1:10,000 were used for L1
and LI-E6/E7 HPV 16 detection, which was carried out by
chemiluminescence (ECL Reagent, Amersham Pharmacia
Biotech). The commercial HPV vaccine Gardasil® was used
as positive control.
ELISA plates (Corning) were coated with 100 μl of crude
extract of tomato fruits or chromatography-purified VLPs
and cVLPs. Gardasil® was used as standard. All samples
were tested in triplicate. Plates were incubated for 16 h at
4°C, washed twice in TBS-0.1% Tween 20 and blocked by
addition of 2%w/v bovine serum albumin in TBS-0.1%
Tween 20 with 2 h incubation at 37°C. Plates were
washed four times, and incubated with sera at 1:500 in
blocking buffer from women vaccinated with three doses
of commercial vaccine. After 2 h at 37°C, plates were
washed 6 times and incubated with 1:5000 rabbit-anti
human IgG (Zymed, USA). The plates were incubated forVirology Journal 2009, 6:2 http://www.virologyj.com/content/6/1/2
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a further 2 h at 37°C. After eight washes, alkaline phos-
phatase substrate (Sigma) was diluted in a 10% dieth-
anolamine solution (pH 9.8) and added to the plates. The
absorbance (405 nm) was determined in an ELISA plate
reader. The concentration of VLPs was calculated by aver-
age of three repeats.
Electron microscopy
Non-transfected and tranfected L1 fruits were ground
under liquid nitrogen. The resulting powder was sus-
pended in 5 volumes of extraction buffer PBS, pH 7.2, in
the presence of the protease inhibitor cocktail (Sigma)
and kept on ice. The suspension was clarified by centrifu-
gation (30 min at 1,500 × g, followed by 30 min at 10,000
× g). The clarified supernatants were then centrifuged at
high speed (3.5 h at 100,000 × g), and the final pellets
were resuspended in 1 ml of PBS. Twenty microliters of
this suspension were mixed with an equal volume of 2%
phosphotungstic acid for 5 min. The mix was placed on
Formvar grids for 30 min and excess liquid absorbed with
a soft tissue. The grids were imaged on a Philips Morgagni
268 transmission electron microscope. Commercial vac-
cine at 1:50 dilution in PBS was used as positive control.
VLP and cVLP purification
Tomatoes from HPV 16 L1 and HPV 16 L1 E6/E7 trans-
genic plants, were lysed with extraction buffer (PBS pH
7.4 with 1 mM PMSF) on ice. The homogenates were clar-
ified by centrifugation at 10,000 rpm for 30 min at 4°C
and filtered on Whatman paper No. 1 and then on Milli-
pore 0.8 μM filter. The supernatant was then applied on to
an affinity column, prepared by coupling sera from
women vaccinated with three doses of the commercial
vaccine to 4B CNBr-Sepharose (Sigma). The columns were
washed with 50 vol of washing buffer (50 mM Tris-HCl, 5
mM EDTA, 150 mM NaCl, 0.1% NP-40, pH 7.4), fol-
lowed by 50 vols of the same buffer without NP-40. VLPs
were eluted with 100 mM HCl-glycine, pH 4.0. The VLP-
containing fractions were neutralized with 100 mM Tris-
HCl (pH 9.0) and dialyzed against PBS overnight. The
amount of plant-purified VLP/cVLP in fractions was meas-
ured by ELISA as previously described, using commercial
vaccine as standard.
Immunization of mice
Groups of 6 eight week-old C57BL/6 mice (H2-Db) (Har-
lan) were immunized as follows: one group was immu-
nized intraperitonally and boosted 2 weeks later with 5 μg
Expression vectors Figure 7
Expression vectors. Map showing the Ti region of constructs (A) L1 and (B) L1-E6/E7. The promoter and the terminator 
(Ter) employed were from the Cawliflower Mosaic Virus. The bold line represents the EcoRI/BamH1 fragment (670 bp) that 
was used as probe for both Southern and northern blot analysis. LB: Left border, RF: Right border.
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of VLPs alone in the presence of complete Freund's adyu-
vant (CFA), another with cVLPs and CFA and a third
group with 5 μg of commercial vaccine (Gardasil®).
Another group was immunized with 2 doses of 100 μg
HPV 16 E749-57 (RAHYNIVTF, H-2Db-restricted) peptide
(Invitrogen) and the other one received CFA according to
the same schedule. Two weeks after the booster immuni-
zation, blood was obtained from each mouse and used to
determine serum antibody titers. The mice were then sac-
rificed to remove the spleen to obtain T lymphocytes and
then used for cytotoxic assays.
ELISA for detecting anti-VLP antibodies
To determine the specific antibody titers in VLPs
(Gardasil®, HPV 16 L1 and HPV 16 L1E6/E7)-immunized
mice, 100 μl of Gardasil-derived VLPs at 1000 ng/ml
diluted in PBS were used to coat 96-well ELISA plates for
16 h at 4°C. Plates were then washed four times with TBS
containing 0.1% Tween 20 (TBS/Tween 20). Non-specific
binding sites were blocked with 200 μl 2% BSA in TBS/
Tween 20 for 2 h at 37°C. After washing, 100 μl serum
samples (diluted from 1:100) were added in triplicate,
and the plates were incubated at 37°C for a further 2 h.
After washing, alkaline phosphatase-conjugated goat anti-
mouse IgG (Zymed, USA) were diluted 1:500 in blocking
buffer and 100 μl was added to each well. The plates were
incubated for 2 h at 37°C. After washing, alkaline phos-
phatase substrate Sigma 104 was diluted in a 10% dieth-
anolamine solution (pH 9.8) and added to the plates. The
absorbance (405 nm) was determined in an ELISA plate
reader. The concentration of VLPs was calculated by aver-
age of three repeats. The assay was considered valid only
when the coefficient of variation of the triplicates was
≤10%. Additionally, all samples were tested on two wells
not coated with peptide to define non-specific reactivity.
The final ELISA value was calculated by subtracting the
non-specific reactivity mean absorbance from the tripli-
cate mean absorbance.
Hemagglutination inhibition assay
Hemagglutination inhibition assays were performed
according to Roden et al. [22]. Mouse blood was collected
in a heparinized tube and erythrocytes separated by cen-
trifugation at 1,000 rpm for 5 min at 4°C, washed twice
with PBS and suspended in dilution buffer (1% BSA in
PBS) at a concentration of 1% (v/v). Purified VLPs (100
ng) were then incubated with various dilutions of sera
samples at room temperature for 2 h, after which the sam-
ples were diluted with an equal volume of the 1% RBC
suspension. Aliquots (100 μl) of the mixtures were trans-
ferred to a round-bottomed, 96-well plate and incubated
for 3 h at 4°C. Spots indicating VLP neutralizing activity
were photographed.
T-cell stimulation and cytotoxicity assays
Primed T cells from spleen of VLP-immunized mice were
re-stimulated using antigenic peptides [23]: HPV 16 E749-
57 (RAHYNIVTF, H-2Db-restricted) and HPV 16 L1 165–
173 peptide (AGVDNRECI, H-2Db-restricted) or 1 μg
commercial vaccine, recombinant, purified VLPs and 100
U/mL of mrIL-2 (R&D Systems). TC-1 cells derived from a
C57BL/6 lung tumor epithelial cells co-transformed with
HPV 16 E6/E7 and c-Ha-ras [39] as well as TC-1 trans-
fected with HPV 16 L1 gene (TC-1/L1) were used as targets
after labeling with 51Cr (Amersham) for 1 h. Different
numbers of effector cells obtained from VLP-immunized
mice in 50 μL of complete medium were incubated and
then 1× 10451Cr-labeled, target cells were added to tripli-
cate wells of 96-well plates in a final volume of 200 μL.
After 4 h at 37°C, 100 μl of supernatant were measured on
a γ-counter (Packard). For each pretreated cell group, 51Cr
labeled cells incubated with 5% Triton X-100 or medium
alone were used to determine maximum and spontaneous
releases. Spontaneous release was usually less than 10%
and never exceeded 15%. The percentage of specific lysis
of each well was calculated as: (experimental release -
spontaneous release)/(maximal release - spontaneous
release) × 100.
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